Ramaraj Radhakrishnan
Department of Internal Medicine, University of Arizona College of Medicine, Tucson, Arizona 85724, USA.
Cardiol Rev. 2008 Jul-Aug;16(4):172-80. doi: 10.1097/CRD.0b013e318178e525.
Hypertrophic cardiomyopathy (HCM) is a disease characterized by primary hypertrophy of the left (and sometimes right) ventricle. The clinical manifestations of the disease are dyspnea, angina, and a continuum encompassing lightheadedness, presyncope, syncope, and sudden death. Although HCM is often caused by an identifiable mutation in a gene coding for a sarcomeric protein and inherited in an autosomal-dominant pattern, many patients do not have any relatives in whom the disease is manifest. The prevalence of HCM is estimated to be 0.2%, with nearly 600,000 Americans affected. This limited exposure of clinicians to HCM understandably accounts for the uncertainty that prevails regarding this disease and its management.
肥厚型心肌病（HCM）是一种以左心室（有时也包括右心室）原发性肥厚为特征的疾病。该疾病的临床表现包括呼吸困难、心绞痛，以及一系列从轻头晕、先兆晕厥、晕厥到猝死的症状。尽管HCM通常由编码肌节蛋白的基因中可识别的突变引起，并以常染色体显性模式遗传，但许多患者并没有患病的亲属。据估计，HCM的患病率为0.2%，近60万美国人受其影响。临床医生对HCM的接触有限，这就不难解释为什么关于这种疾病及其管理存在普遍的不确定性。
